The corona virus was first detected in the UK, named B.1.1.7 and often referred to as the “UK variant” or “Kent variant”, which has been found in more than 50 countries, and one of the UK’s leading scientists to “clear the world”.
Professor Sharon Mayil, executive director and chairman of the Covid-19 Genomics UK (COG-UK) consortium, told the BBC’s News Podcast that the P1.1.7 variant “cleansed the country” and “is going to wipe out the world” in all probability. However, he outlined Govt-19 Vaccines were allowed to be used Seemed to work best in the UK against variants of the virus that spread in the UK.
Jan. ”. The expert panel also said that early analyzes show that there may be an increase in the severity of the disease associated with B1.1.7. Variation.
South Africa Variation
Another cause for concern in the UK is the presence of the E484K mutation (originally found in South Africa) in Kent variant models. “VOC202102 / 02 is a specific cluster characterized by the presence of E484K spike protein mutation in variant VOC202012 / 01 SARS-CoV-2 B1.1.7, which was first detected in the UK by the end of 2020. PHE has so far identified 21 cases of VOC202102 / 02 in the UK, mainly focusing on outbreaks in the south-west of the UK, ”Public Health UK said on 10 February.
However, the PHE underscores that “there is currently no evidence that this mutation alone causes more severe disease or greater prevalence, leading to weaker neutralization by antibodies in laboratory tests”.
“We expect vaccines to prevent more serious illness and death, and we are taking public health action with clusters of variations with E484K to reduce the risk of transmission in our population,” said Dr Susan Hopkins, COVID-19 Strategic Response Director.
UK Variation & India
In India, the incidence of infection with the UK variant is very low. On January 28, the Ministry of Health found genetic sequencing in only 165 samples in the UK.
There is a vaccine called covaxin developed by ICMR and Bharat Biotech Found to work Against the New England variant. In fact, Bharat Biotech is one of the main reasons for obtaining banned emergency use approval in India only on the basis of safety and immunization data from Phase 1 and 2 trials. “Our study highlights the comparable neutralizing activity of sera in vaccinated individuals against variant and hereditary SARS-CoV-2 strains. In particular, sera from vaccinated recipients may neutralize UK-differentiated strains, which eliminates escape uncertainty,” the researchers said.
The Cow Shield of the Serum Institute, the other vaccine offered in India, is a version of the Oxford-Astrogeneca vaccine – which has been found to be effective against the UK variant.